NCT04609319Completed
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
ARIA: Real-world Utilization and Outcomes With Dacomitinib First-line Treatment for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer Among Asian Patients - A Multi-center Chart Review
Source: ClinicalTrials.gov · Last updated 31 May 2025
Brief summary (registry, in English)
This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) treated with dacomitinib as first-line therapy from the date of advanced NSCLC diagnosis to the date of death, lost to follow-up, withdrawal of consent or end of study, whichever occurs first.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 307 (actual)
- First submitted
- 23 Oct 2020
- Start date
- 11 Jun 2021
- Primary completion date
- 28 May 2024
- Lead sponsor
- Pfizer
- Diseases
- Lung cancer
- NCT number
- NCT04609319
What you commit to
- Study type: Observational
- Participants enrolled: 307
- From 11 Jun 2021 to the primary completion date, 28 May 2024
- 14 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Enrolled in any interventional clinical study or trial (however, patients enrolled in non-interventional, real world study may still be included).
Who the study is looking for
- Adult (aged ≥18 years) with histology-confirmed advanced NSCLC (TNM stage IIIB-IV);
- Presence of any EGFR-activating mutation (exon 19 deletion or exon 21 L858R substitution) or other uncommon EGFR mutations prior to anti-cancer treatment;
- Initiating dacomitinib as first-line treatment after confirmation of EGFR-mutation status (ie, no prior treatment with other EGFR TKI or systemic therapy);
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Internal Medicine, Chinese Academy of Medical Sciences Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| The First Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
| Hunan Provincial Tumor Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
| West China Hospital of Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| Guangdong Provincial People's Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| the First Affiliated Hospital of Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| The First Affiliated Hospital of China Medical University Coordinator of this site? Confirm its status | Shenyang, Liaoning Province | China | Unknown status |
| Henan Cancer Hospital Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
| Tata Memorial Center, Kolkata Coordinator of this site? Confirm its status | Kolkata, West Bengal | India | Unknown status |
| Rajiv Gandhi Cancer Institute And Research Centre Coordinator of this site? Confirm its status | New Delhi | India | Unknown status |
| University Malaya Medical Centre Coordinator of this site? Confirm its status | Kuala Lumpur | Malaysia | Unknown status |
| Pantai Hospital Kuala Lumpur Coordinator of this site? Confirm its status | Kuala Lumpur | Malaysia | Unknown status |
| Beacon Hospital Coordinator of this site? Confirm its status | Petaling Jaya | Malaysia | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.